Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001297819
Ethics application status
Approved
Date submitted
13/12/2012
Date registered
17/12/2012
Date last updated
17/12/2012
Type of registration
Retrospectively registered

Titles & IDs
Public title
Does carbon dioxide insufflation during colonoscopy minimise post colonoscopy pain?: A randomised controlled trial
Scientific title
Does carbon dioxide insufflation for a patient during colonoscopy minimise their post colonoscopy pain compared to air.
Secondary ID [1] 281642 0
nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
post colonoscopy pain 287930 0
Condition category
Condition code
Oral and Gastrointestinal 288309 288309 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Carbon dioxide (a medicinal gas) was drawn from a CO2 tank and delivery system to a receptacle and then passed intermitently through the endoscope during the colonoscopy at the control of the endoscopist pressing a button on the hand piece of the endoscope. The intention of gas is to insufflate the colon during colonoscopy.
Intervention code [1] 286182 0
Treatment: Drugs
Comparator / control treatment
` standard treatment` was insufflation of room air drawn from a receptacle (called the air/water bottle), to the endoscope and passed intermitently through the endoscope at the control of the endoscopist pressing a button on the hand piece of the endoscope. The purpose of this gas is to insufflate the colon during colonoscopy.
Control group
Active

Outcomes
Primary outcome [1] 288506 0
A comparison of reported abdominal pain using a self reported 0-10 point numeric rating scale(NRS)
Timepoint [1] 288506 0
Intra procedure (0) and post procedure at 10, 30 and 60 minutes
Secondary outcome [1] 300344 0
Nil
Timepoint [1] 300344 0
Nil

Eligibility
Key inclusion criteria
Patients on the waiting list for elective colonoscopy. These will be new patients with symptoms and also patients for surveillance colonoscopy (for reasons of past history of; colon cancer, adenomas, strong family history of bowel cancer and inflammatory bowel disease)
Minimum age
16 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Age under 16 and over 90
Inability to understand participant information
Patients with severe chronic obstructive pulmonary disease (COPD)
Refusal to participate

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The receptionist send trial invitations to patients within the age criteria off the waiting list. On presenting for their colonoscopy the participatns consent and suitability for inclusion was assessed by a nurse.
allocation concealment by sealed randomisation envelopes: Envelopes (120) numbered for men and 12 for women. Inside the envelope it was stated on a slip of paper either the experimental `CO2 or `usual` ( the control air group)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
simple randomisation using an excel computer programme used to allocate numbers to envelopes
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
SPSS 17.0 software. Differences in mean numeric rating scale scores analysed using independent samples t-tests. Chi-squared test for independence was used to assess the differences between the proportions of those reporting 0 pain at four time intervals. The p value was set at < 0.05.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/07/2008
Actual
1/07/2008
Date of last participant enrolment
Anticipated
30/01/2009
Actual
30/01/2009
Date of last data collection
Anticipated
Actual
Sample size
Target
240
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 4749 0
New Zealand
State/province [1] 4749 0
Palmerson North

Funding & Sponsors
Funding source category [1] 286461 0
Hospital
Name [1] 286461 0
MidCentral Health District Health Board
Country [1] 286461 0
New Zealand
Primary sponsor type
Hospital
Name
MidCentral District Health Board
Address
PO box 2056
Palmerston North, 4410
New Zealand
Country
New Zealand
Secondary sponsor category [1] 285250 0
None
Name [1] 285250 0
none
Address [1] 285250 0
none
Country [1] 285250 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288538 0
Health and Disability Ethics Committee (Central Regional Ethics Committee
Ethics committee address [1] 288538 0
Ethics committee country [1] 288538 0
New Zealand
Date submitted for ethics approval [1] 288538 0
12/02/2008
Approval date [1] 288538 0
28/03/2008
Ethics approval number [1] 288538 0
CEN/08/01/005

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 36494 0
Mrs Anne Cleland
Address 36494 0
Gastroenterology Department
MidCentral Health
PO box 2056
Palmerson North, 4410
Country 36494 0
New Zealand
Phone 36494 0
+64 6 3508865
Fax 36494 0
+64 6 3508807
Email 36494 0
anne.cleland@midcentraldhb.govt.nz
Contact person for public queries
Name 36495 0
Anne Cleland
Address 36495 0
Gastroenterology Department
MidCentral Health
PO box 2056
Palmerston North, 4410
Country 36495 0
New Zealand
Phone 36495 0
+64 6 3508865
Fax 36495 0
+64 6 3508807
Email 36495 0
anne.cleland@midcentraldhb.govt.nz
Contact person for scientific queries
Name 36496 0
Anne cleland
Address 36496 0
Gastroenterology Department
MidCentral Health
PO box 2056
Palmerston North, 4410
Country 36496 0
New Zealand
Phone 36496 0
+64 6 3508665
Fax 36496 0
+64 6 3508807
Email 36496 0
anne.cleland@midcentraldhb.govt.nz

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.